These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37125127)

  • 1. Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin.
    Chudhary HRF; Ali A; Bibi S; Waqas M; Rafique S; Idrees M; Halim SA; Abdellattif MH; Khan A; Al-Harrasi A
    ACS Omega; 2023 Apr; 8(16):14784-14791. PubMed ID: 37125127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.
    Mehta R; Kabrawala M; Nandwani S; Desai P; Bhayani V; Patel S; Parekh V
    J Clin Exp Hepatol; 2018 Mar; 8(1):3-6. PubMed ID: 29743790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Expression of
    Afzal M; Ali A; Sheikh N; Rafique S; Idrees M
    J Interferon Cytokine Res; 2020 Jun; 40(6):301-309. PubMed ID: 32486887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
    Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
    Ahmed S; Hassan E; Gomaa A; Esamat G; Ramadan A; Ahmed M; Elsayed A; A Wahsh E
    Curr Drug Saf; 2023; 18(2):207-213. PubMed ID: 35538812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.
    Abdel-Aziz AM; Ibrahim MA; El-Sheikh AA; Kamel MY; Zenhom NM; Abdel-Raheim S; Abdelhaleem H
    J Clin Exp Hepatol; 2018 Mar; 8(1):15-22. PubMed ID: 29743792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
    Poordad F; Shiffman ML; Ghesquiere W; Wong A; Huhn GD; Wong F; Ramji A; Shafran SD; McPhee F; Yang R; Noviello S; Linaberry M;
    Antivir Ther; 2019; 24(1):35-44. PubMed ID: 30382942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    Abdallah F; Mohamed G; Ibrahim M; El Tarabily M
    Am J Med Sci; 2018 May; 355(5):456-466. PubMed ID: 29753376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.
    Kanda T; Nakamoto S; Nakamura M; Jiang X; Miyamura T; Wu S; Yokosuka O
    J Clin Transl Hepatol; 2014 Mar; 2(1):1-6. PubMed ID: 26356295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    Elbaz T; Abdo M; Omar H; Hassan EA; Zaghloul AM; Abdel-Samiee M; Moustafa A; Qawzae A; Gamil M; Esmat G
    J Med Virol; 2019 Feb; 91(2):272-277. PubMed ID: 30138531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir: A Review in Chronic Hepatitis C.
    Keating GM
    Drugs; 2016 Sep; 76(14):1381-91. PubMed ID: 27550544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Yu ML
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.